Page last updated: 2024-12-05

n-nitrosopyrrolidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-nitrosopyrrolidine (NPYR) is a potent carcinogen found in a variety of processed foods, particularly those containing cured meats, smoked fish, and fried foods. It forms during the curing process of meat products through the reaction of nitrite with secondary amines, like pyrrolidine, which are naturally present in food. NPYR is considered a probable human carcinogen by the International Agency for Research on Cancer (IARC). Studies have shown that it can cause tumors in various organs, including the liver, stomach, and esophagus, in animal models. The mechanism of NPYR's carcinogenic activity involves its ability to alkylate DNA, leading to mutations that can contribute to cancer development. Research into NPYR focuses on understanding its formation pathways, its role in cancer development, and the development of methods to minimize its presence in food products. This includes exploring alternative curing methods, using nitrite substitutes, and developing analytical techniques to detect and quantify NPYR in food.'

N-Nitrosopyrrolidine: Carcinogenic nitrosamine that may be formed from preservatives in meats during their preparation or in the liver during metabolism. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID13591
CHEMBL ID351175
CHEBI ID82362
SCHEMBL ID606668
MeSH IDM0014402

Synonyms (67)

Synonym
n-pyr
ccris 478
einecs 213-218-8
hsdb 5116
n-nitrosopyrrolidin [german]
rcra waste no. u180
ai3-62030
brn 0107615
pyrrole, tetrahydro-n-nitroso-
rcra waste number u180
nsc 18797
1-nitroso-pyrrolidine
n-nitrosopyrrolidin
930-55-2
pyrrolidine, 1-nitroso-
no-pyr
nitrosopyrrolidine
nsc18797
n-nitrosopyrrolidine
nsc-18797
1-nitrosopyrrolidine
npyr
1-pyrrolidinamine, n-nitroso-
wln: t5ntj ano
1-nitrosopyrrolidine, 99%
inchi=1/c4h8n2o/c7-5-6-3-1-2-4-6/h1-4h
1-nitrosopyrrolidine-d4
CHEMBL351175
chebi:82362 ,
NCGC00249214-01
35884-45-8
pyrrolidine, nitroso-
C19285
unii-sz4j5wk201
sz4j5wk201 ,
5-20-01-00521 (beilstein handbook reference)
tox21_302913
dtxsid8021062 ,
cas-930-55-2
NCGC00256421-01
dtxcid701062
NCGC00259905-01
tox21_202356
AKOS006227868
FT-0633121
SCHEMBL606668
n-nitrosopyrrolidine [iarc]
n-nitrosopyrrolidine [mi]
n-nitrosopyrrolidine [hsdb]
WNYADZVDBIBLJJ-UHFFFAOYSA-N
1219802-09-1
n-nitrosopyrrolidine-d8
n-nitroso-pyrrolidine
n-nitrosopyrrolidine 100 microg/ml in methanol
pyrrolidine, 1-nitroso-; 1-nitrosopyrrolidine; n-nitrosopyrrolidine; npyr; nsc 18797
n-nitrosopyrrolidine 10 microg/ml in methanol
tetrahydro-n-nitroso-pyrrole
n-nitroso-1-pyrrolidinamine
nitroso-pyrrolidine
n-nitrosopyrrolidine (npyr)
BS-17894
Q22138421
57371-40-1
D82025
mfcd00003166
SY115826
EN300-1296527

Research Excerpts

Dosage Studied

ExcerptRelevanceReference
" There were 5 individual groups in which the effects of different periods of dosing and varying intervals without treatment were compared."( Comparison of liver tumor frequencies after intermittent oral administration of different doses of N-nitrosopyrrolidine in Sprague-Dawley rats.
Habs, M; Hoos, A; Schmähl, D, 1985
)
0.49
" There were four experimental groups in which the effects of different periods of dosing and varied intervals without treatment were compared."( Effect of the intermittent administration of N-nitrosopyrrolidine (NPYR) on the tumor incidence in Sprague-Dawley rats.
Habs, H; Habs, M; Schmähi, D, 1980
)
0.52
" Our findings indicate that the RDLMN assay could be a useful tool for comprehensive risk assessment of carcinogenicity by providing information on both genotoxicity and histopathology when integrated into a general repeat dosing toxicity assay."( Evaluation of repeated dose micronucleus assays of the liver using N-nitrosopyrrolidine: a report of the collaborative study by CSGMT/JEMS.MMS.
Abe, M; Furukawa, S; Hagioa, S; Hayashi, S; Kawasako, K; Kuroda, Y; Ogawa, I; Wako, Y, 2015
)
0.65
" The AEM converted anions in the eluent to hydroxide ions after HPLC separation and increased eluent pH, allowing for the subsequent photochemical reactions, which are otherwise achieved by pH conditioning with an additional dosing pump of basic chemical."( An inline ion-exchange system in a chemiluminescence-based analyzer for direct analysis of N-nitrosamines in treated wastewater.
Fujioka, T; Ishida, KP; Kodamatani, H; Maruyama, N; Masunaga, H; Plumlee, MH; Roback, SL, 2018
)
0.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
pyrrolidinesAny of a class of heterocyclic amines having a saturated five-membered ring.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency83.42360.007215.758889.3584AID1224835
acetylcholinesteraseHomo sapiens (human)Potency13.22180.002541.796015,848.9004AID1347395
hypoxia-inducible factor 1 alpha subunitHomo sapiens (human)Potency11.47653.189029.884159.4836AID1224846
RAR-related orphan receptor gammaMus musculus (house mouse)Potency10.14350.006038.004119,952.5996AID1159521
AR proteinHomo sapiens (human)Potency32.07660.000221.22318,912.5098AID1259243
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency21.47380.000657.913322,387.1992AID1259377; AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency46.29480.001022.650876.6163AID1224838; AID1224839
progesterone receptorHomo sapiens (human)Potency20.23900.000417.946075.1148AID1346795
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency11.38120.003041.611522,387.1992AID1159552
retinoid X nuclear receptor alphaHomo sapiens (human)Potency16.21100.000817.505159.3239AID1159527
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency37.05700.001530.607315,848.9004AID1224841; AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency20.23900.000229.305416,493.5996AID1259244
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency11.47650.057821.109761.2679AID1159526
Histone H2A.xCricetulus griseus (Chinese hamster)Potency16.72400.039147.5451146.8240AID1224845
Voltage-dependent calcium channel gamma-2 subunitMus musculus (house mouse)Potency20.23900.001557.789015,848.9004AID1259244
Glutamate receptor 2Rattus norvegicus (Norway rat)Potency20.23900.001551.739315,848.9004AID1259244
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
plasma membraneGlutamate receptor 2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID592889Mutagenic activity in Salmonella Typhimurium TA98 assessed as number of revertants after 44 hrs by Ames test in presence of rat liver S9 fraction2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
7-azabicyclo[2.2.1]heptane as a structural motif to block mutagenicity of nitrosamines.
AID592887Mutagenic activity in Salmonella Typhimurium TA100 assessed as number of revertants after 44 hrs by Ames test in presence of rat liver S9 fraction2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
7-azabicyclo[2.2.1]heptane as a structural motif to block mutagenicity of nitrosamines.
AID592890Mutagenic activity in Salmonella Typhimurium TA98 assessed as number of revertants after 44 hrs by Ames test2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
7-azabicyclo[2.2.1]heptane as a structural motif to block mutagenicity of nitrosamines.
AID592888Mutagenic activity in Salmonella Typhimurium TA100 assessed as number of revertants after 44 hrs by Ames test2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
7-azabicyclo[2.2.1]heptane as a structural motif to block mutagenicity of nitrosamines.
AID226734Carcinogenic potency modelled in silico, (w = weak carcinogen)1982Journal of medicinal chemistry, Jul, Volume: 25, Issue:7
Computer-assisted studies of structure-activity relationships of N-nitroso compounds using pattern recognition.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (151)

TimeframeStudies, This Drug (%)All Drugs %
pre-199080 (52.98)18.7374
1990's28 (18.54)18.2507
2000's22 (14.57)29.6817
2010's20 (13.25)24.3611
2020's1 (0.66)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.08 (24.57)
Research Supply Index5.18 (2.92)
Research Growth Index4.28 (4.65)
Search Engine Demand Index46.20 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (0.57%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other175 (99.43%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]